AmgenNow Program Enhances Access to Repatha for Patients

Amgen Launches AmgenNow for Direct Access to Repatha

Today, Amgen has unveiled a remarkable consumer initiative known as AmgenNow, designed to elevate patient access to Repatha (evolocumab), a treatment proven to significantly reduce the risk of major adverse cardiovascular events. This program offers a substantial discount, which is nearly 60% off the current list price, enabling eligible patients to acquire Repatha for only $239 monthly.

Empowering Patients with Affordable Medication

AmgenNow is a groundbreaking step in ensuring that more patients can obtain necessary medications, especially those who are uninsured or face high deductibles. The program welcomes everyone who might prefer to pay out of pocket. With this pricing, Amgen solidifies its commitment to making healthcare accessible, ensuring that American patients have a beneficial pathway to important treatments.

A Commitment to Healthcare Affordability

Murdo Gordon, Amgen's executive vice president of Global Commercial Operations, emphasizes the company's dedication to enhancing patient care. "Over five million patients have already benefited from Repatha," he stated. Going a step further, the AmgenNow program aims to simplify the process for uninsured patients or those who choose to self-pay, in turn allowing a greater number of individuals at risk of major cardiovascular events to access this effective treatment.

Accessibility for All Patients Nationwide

Starting from today, all patients using Repatha will have access to AmgenNow, regardless of their participation in government programs like Medicare or Medicaid. This initiative liberates patients from the constraints often tied to insurance requirements, such as step therapy or prior authorization, which can delay treatment.

A Revolutionary Step in Drug Distribution

Additionally, AmgenNow will soon be made available through the TrumpRx website, further expanding its reach. This direct-to-patient model represents a significant shift in how medications like Repatha are distributed, reflecting the evolving nature of pharmaceutical care and accessibility.

Understanding Repatha and Its Benefits

Repatha is a monoclonal antibody that plays a critical role in combating hypercholesterolemia and associated cardiovascular risks. By inhibiting the action of proprotein convertase subtilisin/kexin type 9 (PCSK9), Repatha enhances the liver's ability to clear low-density lipoprotein (LDL) cholesterol from the blood, which is pivotal in lowering bad cholesterol levels and thereby reducing cardiovascular threats. Over the past 15 years, its safety and efficacy have been validated through numerous clinical trials involving more than 57,000 patients.

Global Approval and Indications for Repatha

Repatha is approved in over 74 countries, including the United States and member nations of the European Union. It is specifically indicated for individuals at increased risk for serious cardiovascular events, assisting in lowering LDL cholesterol levels whether they are adults with hypercholesterolemia or pediatric patients with familial hypercholesterolemia (HeFH or HoFH).

Safety Information for Patients

While Repatha presents a robust solution for cholesterol management, patients should be aware of possible hypersensitivity reactions and be cautious if they have a history of serious reactions to the medication. Common side effects reported include nasopharyngitis, upper respiratory infections, and possible injection site reactions, although these effects are generally manageable and reversible.

Amgen's Ongoing Commitment to Innovation

With over four decades of experience in biopharmaceutical innovation, Amgen continues to be at the forefront of scientific advancements. The company not only discovers and develops medicines but also manufactures and delivers new therapies that address some of the most challenging diseases faced globally.

Acknowledgments and Recognitions

Recently, Amgen was acknowledged as one of the "World's Most Innovative Companies" by Fast Company, showcasing various accolades that highlight its contributions to healthcare. As a leading player on the Nasdaq-100 Index and part of the Dow Jones Industrial Average, Amgen exemplifies growth and commitment to patients worldwide.

Frequently Asked Questions

What is the purpose of the AmgenNow program?

The AmgenNow program aims to make Repatha more accessible and affordable for patients, significantly reducing the medication's cost.

Who is eligible for the AmgenNow program?

All Repatha patients, including those who are uninsured or on high-deductible plans, can benefit from the AmgenNow program.

How much does Repatha cost through AmgenNow?

Repatha will be offered through AmgenNow at a significantly reduced monthly price of $239.

How does Repatha work?

Repatha helps lower bad cholesterol by inhibiting PCSK9, which allows more LDL receptors in the liver to clear LDL cholesterol from the bloodstream.

Where can I learn more about Amgen's offerings?

For additional information regarding Amgen's products and programs, you may visit Amgen.com.

About The Author

Greetings, I'm 32-year-old author and financial specialist Evelyn Baker. My introduction into the financial industry started with an economics degree and continued with a wealth of experience in wealth management and financial consulting. My great passion over the years has been assisting people and companies in making wise, well-informed decisions to reach their financial objectives.

My goal with writing is to simplify difficult financial ideas into understandable, doable guidance. My goal in writing many books and articles is to make personal finance understandable to everyone, irrespective of their experience or background. I want to give readers the information they need to take charge of their financial futures, from investing and retirement planning to budgeting and saving.

Along with my writing, I lead webinars and workshops where I provide doable advice and methods for achieving financial success. To reach a larger audience, I also frequently contribute to financial blogs and publications. My method is always to offer doable, real-world guidance that can actually improve people's lives.

Aside from my job, I like to cook, travel, and experience other cultures. I work hard to apply my belief in the value of a balanced life to my financial counsel. My goal in working is to encourage and enable people to succeed financially so they may lead the best lives possible.

Contact Evelyn Baker privately here. Or send an email with ATTN: Evelyn Baker as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.